• Methylthioadenosine (MTA) is elevated in MTAP-deleted cancer cells in vitro, which provides a selective vulnerability to PRMT5 and MAT2A inhibitors • Accumulation of MTA in MTAP-deleted cancer cells is predominately extracellular, suggesting active secretion of MTA.
In Brief
The co-deletion of MTAP in the CDKN2A locus is a frequent event in diverse cancers including glioblastoma. Recent publications report that significant accumulations of the MTAP substrate, methylthioadenosine (MTA), can sensitize MTAP-deleted cancer cells to novel inhibitors of PRMT5 and MAT2A for targeted therapy against tumors with this particular genetic alteration. In this work, using comprehensive metabolomic profiling, we show that MTA is primarily secreted, resulting in exceedingly high levels of extracellular MTA in vitro. We further show that primary human glioblastoma tumors minimally accumulate MTA in vivo, which is likely explained by the metabolism of MTA by MTAP-competent stromal cells. Together, these data challenge whether the metabolic conditions required for therapies to exploit vulnerabilities associated MTAP deletions are present in primary human tumors, questioning their translational efficacy in the clinic.
Therapeutic targeting of PRMT5 in MTAP-homozygous deleted cancer cells has thus been upheld as a promising strategy to prevent methylosome organization, selectively killing cancer cells (Figure 1a) (Kryukov et al., 2016; Marjon et al., 2016; Mavrakis et al., 2016) . Another approach leverages the relationship between PRMT5 and Sadenosylmethionine (SAM) (Chan-Penebre et al., 2015; Marjon et al., 2016; Pathania et al., 2017) . SAM is the natural substrate and MTA is a substrate competitive inhibitor of PRMT5. Lowering levels of SAM would thus exacerbate the inhibitory effect of elevated MTA. Accordingly, inhibition of methionine adenosyl transferase (MAT2A), which generates SAM, has also been upheld as a potential therapeutic target in MTAPhomozygous deleted cancers (Figure 1a ) (Chan-Penebre et al., 2015; Marjon et al., 2016; Pathania et al., 2017) , which has progressed all the way to an ongoing phase I trial (NCT03435250).
Both of the aforementioned therapeutic approaches are predicated on there being exceedingly high levels of MTA in MTAP-deleted cancer cells compared to MTAP-intact tissues. While it may seem natural that MTAP-homozygous deleted primary human tumors should also display this phenotype, recent reports identifying this intriguing vulnerability have not actually measured the levels of MTA in primary human tumors (Marjon et al., 2016; Mavrakis et al., 2016) . In fact, we could not find any studies in the literature that reported MTA measurements in actual primary human tumors with an established MTAP genotype. Through combined analysis of both public domain data from previous metabolomics profiling studies and our own data generated in MTAPhomozygous deleted primary human GBMs, we found that the dramatically elevated levels of MTA found in glioma cell lines cannot be extrapolated to primary GBMs. A series of metabolomics studies in cell culture and on primary tumors converge on the observation that accumulation of MTA in culture is a predominately extracellular phenomenon, suggesting secretion out of MTAP-deleted cells. Expounding on this finding in primary tumors, our data strongly suggest that the abundance of nonmalignant MTAP-WT stromal cells metabolize the secreted MTA from the MTAPhomozygous deleted GBM cells. As the promise of synthetic lethal therapies against MTAP-homozygous deleted cancers are premised on vast, intracellular accumulations of MTA, our data caution against the expedient translation of the MTAP-deletion targeted precision therapies to the clinic and strongly contend for more research into the fundamental metabolic differences between model systems and primary tumors.
RESULTS

In vitro MTA accumulation in MTAP-deleted cells is primarily an extracellular phenomenon
MTA is a small, neutral, sulfur-containing nucleoside, which suggests that it may permeate the cell membrane through a nucleoside transporter or perhaps even via passive diffusion. Metabolic profiling studies using independent metabolomics platforms have uniformly concluded that intracellular levels of MTA are elevated >20-fold in vitro (Batova et al., 1996; Iizasa et al., 1984; Kamatani and Carson, 1980; Li et al., 2019; Marjon et al., 2016; Stevens et al., 2009 Stevens et al., , 2010 . However, the extent to which these studies clarify between intracellular and extracellular distribution is not always apparent.
In the studies that have differentiated between the two, increases in MTA in MTAPhomozygous deleted versus WT cell lines are actually quite modest (Ortmayr et al., 2019) . For instance, in the NCI-60 profiling study of Ortmayr et al, which focused exclusively on intracellular metabolites (extensive washing of cell pellet), there is only ~15% increase in MTA in MTAP-deleted compared to WT cancer cell lines (Supplementary Figure S1a) . However, a collaboration between Metabolon Inc and the NCI using the NCI-60 panel did not specify whether washing of the cell pellet was performed and reported a 3-fold increase in MTA in MTAP-deleted compared to intact cell lines (Supplementary Figure S1b) . Even more strikingly, re-analysis of one notable study that conducted mass-spectrometry profiling on conditioned media (secreted metabolites); showed >100-fold increases in MTA in MTAP-deleted cell lines compared to intact cell lines (Supplementary Figure S1c ; for comparison with lactate, see Supplementary Figure S1d (Dettmer et al., 2013) ). The micromolar extracellular levels of MTA reported sharply contrasts the nanomolar to picomolar levels of MTA typically found in conditioned media of MTAP-WT cells (Kirovski et al., 2011; Stevens et al., 2010) . Suffice to say, micromolar concentrations of extracellular MTA in are biochemically outstanding. Indeed, we find that MTA is abundant enough in conditioned media of MTAP-deleted U87 glioma cells, to be detectable by relatively insensitive techniques such as NMR (see below). Though the general trend of increased levels of MTA in MTAP-deleted cell lines was consistent across all experiments, the magnitude of intracellular accumulation was strongly dependent on how extensively the cells were washed prior to metabolite extraction. Less vigorous washing of the cell pellet may give the appearance of high levels of intracellular MTA by inadvertently including the abundant extracellular MTA in the media.
To independently investigate the likelihood of export from MTAP-deleted glioma cells, we compared the concentrations of MTA from the intra-and extracellular environments of three verified MTAP-null cell lines: U87, Gli56, SW1088 (Figure 2a ). Both the extensively washed cell pellet and conditioned media were profiled using the Beth Israel Deaconess Medical Center (BIDMC) platform. Strikingly, the modest intracellular increases of MTA, were vastly overshadowed by extracellular levels MTA, again evidencing secretion (Figure 2b vs. 2c). To corroborate our findings, we also performed a time-course experiment for MTAP-deleted and MTAP-WT cell lines. At given time points, we added new media before profiling both the intracellular (cell pellet) and extracellular metabolites (conditioned media). Though a time-dependent increase was apparent in both the metabolite profiles, it was exacerbated in the extracellular profile (Figure 2d) . This imbalance further supported active MTA secretion. A comparison of intracellular and extracellular levels of MTA, adenosine (nucleoside precursor), SAM and the structural analogue of MTA, methyladenosine, clearly demonstrates the tight regulation of intracellular retained versus secrete metabolites (Figure 2d-g) . Unlike the exclusively intracellular presence of adenosine and SAM, MTA and methyladenosine gradually accumulate extracellularly, suggesting that both are actively extruded.
While the precise mechanism of MTA transport remains underexplored, its identity as an uncharged, sulfur-containing nucleoside makes passive diffusion or movement by adenosine transporters likely (Iizasa et al., 1984; Munshi et al., 1988; Plagemann and Wohlhueter, 1980) . That adenine transporters are known to have broad substrate specificity further substantiates this explanation (Munshi et al., 1988; Plagemann and Wohlhueter, 1980) . For comparison, the anionic metabolite, 2-hydroxyglutarate, has a distinctly intracellular presence, owing to its highly polar nature and absence of any substrate-specific transporters to facilitate its exit out of the cell. Both our data and structure-based-logic are supported by similar observations in other cancer models (Kamatani and Carson, 1980; Kirovski et al., 2011; Limm et al., 2014; Stevens et al., 2010) . In fact, direct measurement of MTA secretion into culture medium out of MTAPdeleted cells was found to occur at a rate of 0.58 to 0.70 nmol/hr/mg of protein in a leukemia cell culture model (Kamatani and Carson, 1980) compared to < 0.1 for MTAP WT leukemia. Paired with these previous studies, our findings build a compelling case for MTA export in MTAP-deleted glioma cells and likely all cancer cell lines.
Metabolomic profiling data from independent platforms do not corroborate a strong elevation of MTA in MTAP-homozygous deleted primary human GBM
Metabolomics analyses of primary human GBM tumors are sparsely reported in the literature. The few studies that have been conducted have favored comparison between tumor populations at different stages or grades, rather than considering the unique metabolic landscape of individual tumors (Erb et al., 2008; Hakimi et al., 2016; Prabhu et al., 2019; Sahu et al., 2017; Xu et al., 2019) . In accordance with the proclivities of the field, we first queried supplemental data from studies using the Metabolon Inc platform on primary human GBMs (Chinnaiyan et al., 2012; Prabhu et al., 2019) . As these studies were focused on identifying differences in metabolites between different glioma grades, no genomics of individual tumors were available. We thus sought to match the metabolomics data on different glioma grades with the reported frequency of MTAP deletions in different glioma grades. Previous studies have shown that the incidence of CDK2NA/MTAP homozygous deletion in grade II glioma is less than 3%; for grade II/III glioma it is never more than 10%. In sharp contrast, the frequency high as 50 percent in GBM (Brennan et al., 2013; Cancer Genome Atlas Research Network et al., 2015; Parsons et al., 2008) . We would thus expect that the matched elevations of MTA would correspond to the aforementioned deletion frequencies per tumor grade, with higher levels of MTA in GBM and considerably lower levels especially in grade II glioma.
However, despite these discordant frequencies in MTAP-homozygous deletion status, analysis of MTA levels from among different glioma grades actually shows similar levels of MTA in grade II/III, grade III and grade IV (GBM) tumors (Chinnaiyan et al., 2012) ( Supplementary Figure S3a,b) . Importantly, no extreme outliers in MTA were evident.
At best, the highest levels of MTA in individual GBM cases are just about 2-fold higher than the median of (MTAP-WT) lower grade glioma tumors. This evidently runs contrary to the expected phenotype in MTAP-homozygous deleted tumors. For comparison, these data also run in stark contrast to the extreme elevations (>100-fold) in 2hydroxyglutarate driven by IDH mutations (Supplementary Figure S3c) . To corroborate these findings, we analyzed metabolomics data obtained from the Metabolon Inc platform (Prabhu et al., 2018) , which neither showed extreme outliers in GBM-associated MTA nor higher levels of MTA comparing lower grade glioma (Supplementary Figure S4a) .
To extend our in vitro observations on secretion to the in vivo environment, we sought to identify any notable change in MTA levels in cerebrospinal fluid (CSF) of GBM versus lower grade glioma or normal brain. No 1 H NMR based metabolomic study that we could find actually reported increases of MTA in GBM (Shao et al., 2014) . Surprisingly, a study using the BIDMC platform only reported marginal differences between MTA levels in the CSF collected from GBM and that collected from the normal brain (Locasale et al., 2012) (Supplementary Figure S4b) . Given that the frequency of MTAP homozygous deletions in GBM is at least 35%, we would have expected to observe a dramatically higher level of MTA in GBM CSF compared to normal brain CSF. Although there was a 1.5-fold difference between GBM and normal brain, with a p-value of 0.0407 by t-test ( Table 2 in (Locasale et al., 2012) ), this difference becomes non-significant when correcting for multiple hypothesis testing. Even if these data do suggest an underlying trend, this is a far cry from the greater-than-100-fold elevation in secreted MTA for MTAP-deleted cells in culture (Figure 2, Supplementary Figure S1 ).
To answer the question directly, we analyzed MTA levels from our metabolomic profiling data generated with the BIDMC platform in primary tumors with full genomic annotation (Wang et al., 2017) for direct comparison between GBM tumors of verified MTAPdeleted and MTAP-WT genotype. This is the first study that directly addressed the effects of MTAP-deletion in primary human tumors. We find that there is a marginal difference (~1.7-fold higher median levels of MTA when considering the raw data, and ~1.3-fold higher when corrected for loading; Figure 3a , b) between the average levels of MTA in MTAP-intact and MTAP-deleted tumors. Though the individual differences in levels of MTA among the tumors within each population appear to overshadow the seemingly small differences between the two populations, the overall difference between the two groups did meet statistical significance (p < 0.03; by unpaired 2-tailed t-test with unequal variance). However, we note that this marginal elevation pales in comparison to outliers driven by specific genetic events that fully recapitulate metabolic data recorded intracellularly in cell culture, such as the >100-fold increase in the levels of 6-phosphogluconate and 2-hydroxyglutarate, driven by the homozygous deletion of PGD (Molina et al., 2018; Sun et al., 2019) In addition to these mass spec metabolomics studies, large scale (n >100 cases) NMR, HR-MAS metabolomic profiles of GBM have not detected methylthioadenosine in MTAP-deleted tumors even though HR-MAS can usually detect metabolites at a minimum concentration of 1 µM (Elkhaled et al., 2014) . That MTA could still not be detected in these contexts suggests that that less than 1 µM of MTA is present in GBM tumors, which concurs with our conclusion that there are no tumors, regardless of MTAP-deletion status, have outliers in MTA.
Primary GBM tumors are extensively populated by MTAP-expressing stromal cells
To both verify the diagnosis of MTAP-homozygous deletion and contrast this with the extensive levels of MTAP expression in non-malignant tissue, we performed immunohistochemistry. It is already well-established that GBM tumors may have up to 70% stromal cells, including non-transformed reactive astrocytes, lymphocytes, endothelial cells, fibroblasts, and axonal and neuronal remnants (Kim et al., 2015; Wang et al., 2017) . We first validated an MTAP rabbit monoclonal antibody (Clone: [EPR6892], ab126623)) by demonstrating strong staining in formalin fixed paraffin embedded ( MTAP. Together, these staining results support that this antibody accurately quantifies MTAP levels in FFPE slides. Notable among our stained slides was the significant amount of positive staining in normal mouse brain and stromal cells, especially given that xenografts typically grow much less invasively and are less populated by stromal cells compared to human GBMs. By extension, true human GBMs are thus more likely to contain a higher proportion of stromal components such as astrocytes and microglia.
Next, we applied this antibody to primary GBM tumor FFPE sections. Of 60 cases analyzed, we find that approximately 40% of cases show complete lack of MTAP staining in GBM tumor cells, which corresponds to the expected MTAP-deleted frequency in GBM, (Brennan et al., 2013) ; notably, strong staining was observed in nonmalignant stromal cells. The remaining cases show strong, uniform staining in both glioma and stromal cells (representative stained cases are shown in Figure 4 , Supplementary Figure S8 ). The histology of the MTAP-negative primary GBM cases looks quite similar to the MTAP-deleted intracranial xenografted cases, with the exception that the degree of MTAP-positive stromal infiltration is much greater in the primary human GBM tumors compared to xenografts (Supplementary Figure S8 provides a sampling of Primary GBM cases differing in the degree of stromal content).
The lower MTAP-positive stromal content in xenografts is of high relevance as this indicates that xenografted tumors likely underestimate the problem of stromal cell dependent metabolism of tumor cell secreted MTA (Figure 4c ).
Co-culture of MTAP-deleted with MTAP-rescued glioma cell lines abrogates MTA accumulation in conditioned media
We then co-cultured U87 (MTAP-deleted) with U87 MTAP-isogenic rescued cells and determined the effects of MTA accumulation in the media to better model the situation within MTAP-deleted tumors (Figure 4) . Using 1 H-NMR, we measured robust accumulation of MTA in the conditioned media of U87 cells but not D423 (MTAP-intact), or U87 pCMV MTAP (MTAP-rescued glioma) cells (Supplementary Figure S9) . When U87 parental MTAP-deleted glioma cells were co-cultured with U87 MTAP-rescued cells, no MTA is detectable by NMR in conditioned media (Supplementary Figure S10) . This indicates that either U87 MTAP-rescued cells release functional MTAP enzyme into the media or they take up MTA from the media and metabolize it. Either way, this confirms that MTAP-intact cells in the vicinity of MTAP-deleted cancer cells deplete the extracellular accumulation of MTA, negating the selective vulnerability to PRMT5/MAT2A inhibitors conferred by MTAP deletion.
DISCUSSION
We initially embarked on this study in response to the exigence of MTAP-deleted precision therapy endeavors despite lack of exploration of the metabolic state of primary tumors. As the efficacy of MTAP-deletion directed therapies hinges on massive intracellular accumulation of MTA (Fedoriw et al., 2019; Gao et al., 2019; Hörmann et al., 2018; Kryukov et al., 2016; Marjon et al., 2016; Mavrakis et al., 2016) , ensuring that this in vitro phenotype is consistent in human tumors seemed to be a natural and urgent area for investigation. Perhaps surprisingly, none of the recent papers documenting MTAP-dependent vulnerabilities actually reported measurements of MTA in primary human tumors or even xenographed tumors of defined MTAP-deletion status, despite the significant efforts that have been built on the supposition that observed elevations in MTA in vitro would be reflected in primary tumors (Fedoriw et al., 2019; Gao et al., 2019; Hörmann et al., 2018; Kryukov et al., 2016; Marjon et al., 2016; Mavrakis et al., 2016) .
We took to the literature-keen on finding studies describing MTA levels in distinct, genetically defined MTAP-deleted primary tumors-but with little success. We could not find any reports in the literature directly measuring levels of MTA in genomicallyidentified MTAP-deleted versus MTAP-intact primary human tumors, whether GBM or others. This was quite surprising, given that MTA is a metabolite frequently detected in many metabolomic profiling studies. We queried the public domain metabolomic datasets that have been generated using multiple different platforms (Chinnaiyan et al., 2012; Locasale et al., 2012; Sanderson et al., 2019) . While we were unable to locate metabolomic datasets with companion genomic information, we found multiple high quality metabolomic datasets for primary glioma of different grades. Given the high prevalence of MTAP homozygous deletions in grade IV-glioma/GBM (~40%) and contrastingly low frequency in lower grade glioma, comparison of these two tumor sets can proves insightful. If MTAP deletions do indeed lead to MTA accumulation in primary human tumors, we would expect to observe dramatically higher levels of MTA (>20-fold in data from intracellular data in vitro from (Marjon et al., 2016) Figure 3C in that publication) in a substantial fraction of GBM tumors. Data from three independent metabolomic datasets generated from different platforms indicate that the differences in MTA levels, even when considering outliers, are at best, 2-fold higher in purportedly MTAP-deleted versus MTAP-intact tumors. We then interrogated one of our own metabolomic datasets generated from primary and recurrent snap frozen GBM tumors utilizing the BIDMC platform with complementary genomic data (Wang et al., 2017) .
Even if our data may allow for the possibility of marginal difference in levels of MTA between MTAP-deleted and MTAP-WT tumors (1.7-fold or 1.3-fold increase, depending on normalization; p < 0.03), there is extensive overlap between the groups and this is nowhere near the vast elevations in MTA reported for glioma cell lines in vitro.
In the literature, we noticed strong discrepancies in the magnitudes of reported MTAincrease in MTAP-deleted versus MTAP-intact cancer cell lines from different studies (Supplementary Figure 1) . Careful analysis of these results in light of our own in vitro data evidencing far greater accumulations of extracellular, rather than intracellular, MTA points to MTA secretion out of MTAP-deleted cells and the discrepancies from different studies arising from how well intracellular versus extracellular metabolite levels are separated during sample processing. Indeed, similar observations have been previously reported (Kamatani and Carson, 1980; Riscoe and Ferro, 1984) , which further corroborate this finding. Another study also observed extracellular accumulation of MTA in MTAP-deficient cells, but only when cultured with heat-inactivated fetal bovine serum (FBS) or fetal horse serum, which does not contain active MTAP (Riscoe and Ferro, 1984) . Heat-inactivated FBS is currently the standard for cell culture and was thus used in our studies and all other recent MTAP-related studies.
In sum, our findings on massive extracellular accumulations do not extend to our metabolome analyses of MTAP-deleted primary GBM tumors or CSF: at best, marginal elevations in MTA were observed in any of these. A variety of reasons may explain the discrepancy between cell culture and human tumor data. The simplest possible explanation is that the exceedingly high levels of reported intracellular MTA may be due to less vigorous washing of the cell pellet prior to metabolomic profiling. Biochemical differences between cell culture models and the in vivo environment may also be a contributor: MTAP is present in both human plasma (Carrera et al., 1986; Wishart et al., 2007) and in the CSF (Guldbrandsen et al., 2014) , making the conversion of released MTA to S-methyl-5-thio-D-ribose-1-phosphate and adenine possible. Primary tumor environments are also characterized by high stromal content comprised of MTAP-WT cells (Figure 4) . As MTA is a neutral nucleotide, both passive diffusion and movement via adenine transporters (Limm et al., 2014; Munshi et al., 1988) into MTAP-WT cells are possible, though the latter is much more likely (Iizasa et al., 1984; Munshi et al., 1988; Plagemann and Wohlhueter, 1980) . Under this explanation, the net movement and metabolism of MTA by stromal cells makes the absence of any detectable increase in MTA in primary GBMs and CSF of MTAP-deleted tumors self-evident. Finally, we also considered the possibility of discordant levels of the enzymes preceding the MTAP reaction-adenosylmethionine decarboxylase and spermidine or spermine synthasebetween cultured cells and primary GBMs. However, a survey of the Human Protein Atlas shows that expression is comparable amongst the two (e.g. Human Protein Atlas: SRM).
A combination of the above explanations most likely contributes to the cultured cells versus primary tumor discrepancy. It is already well-established that cell culture conditions do not always accurately reflect physiological conditions Sanderson et al., 2019; Vande Voorde et al., 2019) . Prior to in vitro metabolomics profiling, we cultured our cells using heat-inactivated fetal bovine serum which, thereby nullifying any MTAP-activity that would otherwise be present in the serum. The more significant contributor to the primary GBM results may be attributed to the abundance of stromal cells, which may equal or surpass the number of malignant cells-even in very aggressive tumors (Figure 4) . While the metabolomic data are strictly limited to GBM, the secretion versus intracellular accumulation of MTA is evident in cell lines of other cancer types (Supplementary Figure S1) (Su et al., 2011) , and the presence of MTAP in extracellular biological fluids has been documented in whole blood (Ruefli-Brasse et al., 2011) .
Ultimately, these findings are significant because precision therapies targeting MTAPdeleted tumors are predicated on high levels of MTA for efficacy. Reports of high extracellular levels of MTA in MTAP-deleted cells permeate the early biochemical literature. Our results corroborate and, with the advent of metabolomics, offer a more meticulous inspection of global metabolite changes across a range of cell lines and primary GBM tumors. That MTAP deletions can be leveraged as a point of selective vulnerability in myriad cancers has spurred much excitement into finding targetable proteins in its metabolic network. Accordingly, MAT2A has emerged as the pre-eminent target thus far (Kryukov et al., 2016; Mavrakis et al., 2016) . In addition to our aforementioned shortcomings, targeting MAT2A raises a number of independent issues.
MAT2A catalyzes the production of SAM and SAM is evidently essential for biological function on its own. CRISPR/Avana datasets show that, MAT2A (and PRMT5, for that matter) is an essential gene, irrespective of MTAP deletion status (summarized in Figure 1) .
Several other strategies that do not require accumulation of MTA have been proposed to exploit the MTAP-homozygous deletion for the purposes of precision oncology.
Specifically, the purine biosynthesis of methionine biosynthesis defects (Kindler et al., 2009; Ruefli-Brasse et al., 2011; Tang et al., 2018) . But again, the issue of MTAP-WTexpressing stromal cells or MTAP present in extracellular biological fluids is also problematic for in vivo efficacy for these alternative strategies. These hurdles beg the question as to whether the high frequency of MTAP deletions can even be therapeutically actionable in the clinic.
To this end, we offer three different strategies that might overcome the issue of MTA secretion. First, the most obvious is to identify the nucleoside transporters and generate appropriate inhibitors. The second possible solution involves inhibition of extracellular MTAP, if this proves to be as significant a route of MTA metabolism as other have suggested (Ruefli-Brasse et al., 2011) . Though the latter may appear to be a lofty aspiration, we contend there are two fairly straightforward approaches to accomplishing this. First, as the MTAP reaction is a phosphorolysis, it is reasonable to conclude that an MTAP phosphonate transition state analogue may effectively inhibit extracellular MTAP. Transition state inhibitors have, indeed, already been synthesized (Singh et al., 2004) . However, the absence of an anionic phosphate or phosphonate moiety makes these inhibitors cell permeable. This negates the exclusive extracellular MTAP inhibition that would have otherwise occurred had a phosphate or phosphonate moiety been present in these structures. Phosphonates and phosphates are poorly cell permeable (Leonard et al., 2016; Lin et al., 2018) , but distribute well in water, making them ideal to incorporate in inhibitors of extracellular enzymes. A second approach to selectively inhibiting extracellular MTAP would be a neutralizing monoclonal antibody. Such antibodies have been successfully designed for many growth factors and cytokines, and even enzymes (Farady et al., 2007) . Given the near-exclusive extracellular activity of therapeutic antibodies, this may be a viable strategy to neutralize extracellular MTAP-activity and allow MTA to accumulate in MTAP-deleted tumors, thus enabling selective sensitization to inhibitors of PRMT5 and MAT2A. Finally, there may be metabolic methods to force overproduction of MTA. For example, in vitro studies indicate that supplementation of cells with putrescine can increase MTA secretion rates (Kamatani and Carson, 1980) . This is because putrescine is the substrate of spermine synthase, which generates both spermine and MTA (Figure 1b) . Because putrescine is minimally toxic (LD 50 , > 500 mg/kg; TOXNET CASRN: 110-60-1), it could potentially be used pharmacologically for the deliberate exaggeration of MTA accumulation in MTAPdeleted tumors. 
FIGURE LEGENDS
STAR METHODS
Identification of cell lines with MTAP-homozygous deletions
Scoring of homozygous deletions even with robust copy number data can be problematic due to uneven ploidy across cell lines, as well as where deletion boundaries only partially cover the gene, yet eliminate its functional expression. Thus, we sought to identify MTAP functionally null cell lines. For the NCI-60 cell line comparisons, we gathered data from the Sanger Center COSMIC; this data is corrected for ploidy by the ASCAT algorithm (Van Loo et al., 2012) . We utilized confirmed data using cBioPortal with the NCI-60 panel data (Cerami et al., 2012; Reinhold et al., 2012) , and DepMap CCLE as well as the Genentech collection (Klijn et al., 2015) . Where deletion calls were ambiguous (e.g. SF-295), we took at mRNA expression data or literature western blot data (Hörmann et al., 2018; Kryukov et al., 2016; Marjon et al., 2016; Mavrakis et al., 2016) to decide what constituted a functionally MTAP-null cell line. In the NCI-60 cell line panel, the following cell lines lack MTAP: NCI-H322, SK-MEL-5, K-562, SF-268, MALME-3M, ACHN, MDA-MB-231, OVCAR-5, SF-268, CCRF-CEM, SR, MCF-7, and A549.
Cell Culture and Xenograft Generation
The cell lines used in this study that are MTAP-WT: D423 (H423/D423 were conducted according to provider's instructions and as previously described (Leonard et al., 2016) . The U87 MTAP-rescued cell line was generated utilizing the same procedure we previously utilized to generate an ENO1-rescued cell line (PMID: Peak areas from the total ion current for each metabolite SRM transition were integrated using MultiQuant v2.1 software (AB/SCIEX) Intracellular metabolites from cells in culture (cell pellet): Adherent cancer cell lines growing in 10-cm plates at 50-90% confluency were harvested for metabolomic profiling as follows. First, media was removed (and extracted for its own profiling) and the plated cells were washed twice with ice cold 1x PBS (Corning). Cells were then placed in the dry ice and we added 4ml of 80% methanol pre-cooled to -80°C. Then, incubated in the -80°C freezer for 20 min. Cells were scrapped off the plate while on dry ice, placed in pre-cooled tubes and finally centrifugated at maximum speed, 17,000 x g for 5 minutes at 4°C. The supernatant containing polar metabolites was concentrated by speedvacing using an Eppendorf Vacufuge plus (Yuan et al., 2012) and submitted to the BIDMC Mass spec core.
Secreted metabolites (conditioned media): 1-2ml of conditioned media was centrifuged at max speed for 10 minutes to remove any unblocked cells or cell debris. Subsequently, 4 volumes of -80°C pre-cooled methanol for every 1 volume of media was added to make the final concentration of 80% (vol/vol) methanol solution, then vortexed, and left at -80°C for 6-8 hours to precipitate serum and extract polar metabolites. Ice cold methanol media mix, was centrifugedat maximum speed (17,000 x g) for 10 min at 4°C.
Following centrifuging, the supernatant was separated and dried in the speedvac (Eppendorf Vacufuge plus), and was sent to the BIDMC core (Yuan et al., 2012) .
Frozen tumors: Snap liquid nitrogen frozen tumors were kept in the -80°C until extraction and never thawed. Every effort was taken to keep tumors frozen until placed in cold methanol. Frozen tumors were weighed on dry ice without thawing, and placed them in dry ice pre-cooled Fisher Tube #02-681-291 with a Qiagen steel beads. Then, we added 1 ml of 80% at -80°C pre-cooled methanol to each tube. Then, we shacked the tubes with Qiagen Tissue Lyser for 45 s at room temperature at 28
Hz for multiple rounds. We placed the tubes in the dry ice between each round. After samples became homogenous, the final volume of samples were proportioned to 50mg tissue/2ml of 80% methanol. After this step, we kept the samples in -80°C for 24hrs and then vortexed each sample and centrifuged at maximum speed (17,000 x g) for 10 min at 4°C. Then we collect the supernatant and store them in -80°C until speedvacing. For each study, we used Eppendorf Vacufuge Plus to speedvac the same volume of samples. Dried samples were sent to the BIDMC core. Figure S5-S7) . We thus proceeded to utilize this antibody for scoring MTAP homozygous deletions in human primary GBM FFPE sections. IHC was performed as described for the human xenografted tumors. Immunohistochemistry was performed for utilizing citrate antigen retrieval and blocking in 2% goat serum. slides were stained against MTAP (Abcam, rabbit monoclonal ab126623 1:1000, overnight 4 C), and developed with 1x goat anti-rabbit IgG secondary, poly HRP conjugate: thermo scientific, B40962 for 30min at room temp and developed with NOVAred (Vector Labs), or EnzMet (Nanoprobes #6001-30 mL) followed by counterstaining with hematoxylin, or hematoxylin and Eosin. HF2869  HF2869  HF2990  HF2548  HF2898  HF2998  HF3017  HF3050  HF3245  HF3041  HF2934  HF3162  HF3205  HF3081  HF3174  HF2829  HF2959  HF2919  HF3058  HF3186   0   2   4   6   8   10   12   14   16   18   20   HF2869  HF2869  HF2990  HF2548  HF2898  HF2998  HF3017  HF3050  HF3245  HF3041  HF2934  HF3162  HF3205  HF3081  HF3174  HF2829  HF2959  HF2919 HF3058 HF3186 
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